Cargando…
Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer
Carboplatin resistance in ovarian cancer (OV) is a major medical problem. Thus, there is an urgent need to find novel therapeutic targets to improve the prognosis of patients with carboplatin-resistant OV. Accumulating evidence indicates that the gene COL1A1 (collagen type I alpha 1 chain) has an im...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928381/ https://www.ncbi.nlm.nih.gov/pubmed/33680916 http://dx.doi.org/10.3389/fonc.2020.576565 |
_version_ | 1783659844417355776 |
---|---|
author | Yang, Feng Zhao, Ziyu Cai, Shaoyi Ling, Li Hong, Leying Tao, Liang Wang, Qin |
author_facet | Yang, Feng Zhao, Ziyu Cai, Shaoyi Ling, Li Hong, Leying Tao, Liang Wang, Qin |
author_sort | Yang, Feng |
collection | PubMed |
description | Carboplatin resistance in ovarian cancer (OV) is a major medical problem. Thus, there is an urgent need to find novel therapeutic targets to improve the prognosis of patients with carboplatin-resistant OV. Accumulating evidence indicates that the gene COL1A1 (collagen type I alpha 1 chain) has an important role in chemoresistance and could be a therapeutic target. However, there have been no reports about the role of COL1A1 in carboplatin-resistant OV. This study aimed to establish the detailed molecular mechanism of COL1A1 and predict potential drugs for its treatment. We found that COL1A1 had a pivotal role in carboplatin resistance in OV by weighted gene correlation network analysis and survival analysis. Moreover, we constructed a competing endogenous RNA network (LINC00052/SMCR5-miR-98-COL1A1) based on multi-omics data and experiments to explore the upstream regulatory mechanisms of COL1A1. Two key pathways involving COL1A1 in carboplatin resistance were identified by co-expression analysis and pathway enrichment: the “ECM-receptor interaction” and “focal adhesion” Kyoto Encyclopedia of Genes and Genomes pathways. Furthermore, combining these results with those of cell viability assays, we proposed that ZINC000085537017 and quercetin were potential drugs for COL1A1 based on virtual screening and the TCMSP database, respectively. These results might help to improve the outcome of OV in the future. |
format | Online Article Text |
id | pubmed-7928381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79283812021-03-04 Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer Yang, Feng Zhao, Ziyu Cai, Shaoyi Ling, Li Hong, Leying Tao, Liang Wang, Qin Front Oncol Oncology Carboplatin resistance in ovarian cancer (OV) is a major medical problem. Thus, there is an urgent need to find novel therapeutic targets to improve the prognosis of patients with carboplatin-resistant OV. Accumulating evidence indicates that the gene COL1A1 (collagen type I alpha 1 chain) has an important role in chemoresistance and could be a therapeutic target. However, there have been no reports about the role of COL1A1 in carboplatin-resistant OV. This study aimed to establish the detailed molecular mechanism of COL1A1 and predict potential drugs for its treatment. We found that COL1A1 had a pivotal role in carboplatin resistance in OV by weighted gene correlation network analysis and survival analysis. Moreover, we constructed a competing endogenous RNA network (LINC00052/SMCR5-miR-98-COL1A1) based on multi-omics data and experiments to explore the upstream regulatory mechanisms of COL1A1. Two key pathways involving COL1A1 in carboplatin resistance were identified by co-expression analysis and pathway enrichment: the “ECM-receptor interaction” and “focal adhesion” Kyoto Encyclopedia of Genes and Genomes pathways. Furthermore, combining these results with those of cell viability assays, we proposed that ZINC000085537017 and quercetin were potential drugs for COL1A1 based on virtual screening and the TCMSP database, respectively. These results might help to improve the outcome of OV in the future. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7928381/ /pubmed/33680916 http://dx.doi.org/10.3389/fonc.2020.576565 Text en Copyright © 2021 Yang, Zhao, Cai, Ling, Hong, Tao and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Feng Zhao, Ziyu Cai, Shaoyi Ling, Li Hong, Leying Tao, Liang Wang, Qin Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title | Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title_full | Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title_fullStr | Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title_full_unstemmed | Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title_short | Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer |
title_sort | detailed molecular mechanism and potential drugs for col1a1 in carboplatin-resistant ovarian cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928381/ https://www.ncbi.nlm.nih.gov/pubmed/33680916 http://dx.doi.org/10.3389/fonc.2020.576565 |
work_keys_str_mv | AT yangfeng detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT zhaoziyu detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT caishaoyi detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT lingli detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT hongleying detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT taoliang detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer AT wangqin detailedmolecularmechanismandpotentialdrugsforcol1a1incarboplatinresistantovariancancer |